Selective androgen receptor modulators (SARMs) are a novel class of compounds that bind selectively to the androgen receptor to elicit some, but not all, of the effects of testosterone; specifically SARMs increase skeletal muscle mass in both animal and human studies, while sparing prostate effects in men and virilising effects in women. Identified adverse class effects of SARMs include transient elevation of hepatic transaminases and reversible lowering of high-density lipoprotein-cholesterol (HDL-C). This profile makes SARMs attractive as potential anabolic medicines in conditions associated with cachexia, for example, cancer.
女性への男性化作用や男性での前立腺への悪影響の乏しく、主に骨格筋増量をもたらす薬剤で、cachexia含め、男性サルコペニアへの治療に役立つことが期待される
COPDでの筋力低下へのRCT
